Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

22

Revenue 2017

Januvia

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Januvia was produced by Merck & Co..

Takeda pipeline hit by fasiglifam failure

Takeda pipeline hit by fasiglifam failure Takeda had phase III trials ongoing comparing the drug to placebo, Sanofi's Amaryl (glimepiride) and Merck &Co's DPP4 inhibitor Januvia (sitagliptin), as well as a combination trial with DPP4

J&J's combo diabetes drug held up by FDA

J&J's combo diabetes drug held up by FDA Merck &Co and Pfizer are also in this race, and teamed up to combine Merck's already-marketed DPP-4 inhibitor Januvia (sitagliptin) with Pfizer's late-stage SGLT2 inhibitor ertugliflozin

R&D in the firing line as Merck & Co axes 8,500 jobs

R&D in the firing line as Merck & Co axes 8,500 jobs experienced a slowdown in sales growth for its key Januvia (sitagliptin) diabetes franchise.

Deal Watch table for August 2013

Deal Watch table for August 2013 JV. Speciality pharmaceuticals. 200. Merck &Co /. Avanir Pharmaceuticals. Co-promotion. Januvia, Janumet and Jamumet XR in nursing homes.

Avanir to co-promote Merck's diabetes drugs in the US

Avanir to co-promote Merck's diabetes drugs in the US Will market Januvia and Janumet to care homes. Merck &Co and Avanir Pharmaceuticals have entered an agreement to co-promote Merck's portfolio of sitagliptin-based diabetes products in the US. ... Merck will remain responsible for the marketing of

[ Previous 5 results ] 7 8 9 10 11 12 13 14 15 16 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...